恆大高新(002591.SZ)上半年淨虧損453.24萬元 同比轉虧
格隆匯8月9日丨恆大高新(002591.SZ)披露2022年半年度報吿,報吿期內,公司實現營業收入1.74億元,同比下降33.92%;歸屬於上市公司股東的淨利潤-453.24萬元,同比下降122.25%。截至報吿期末,公司總資產11.27億元,較年初增長2.13%;屬於上市公司股東的所有者權益7.71億元,較年初減少0.70%。
2022年半年度,新冠疫情影響了公司在市場開拓、研發、生產交付等方面的工作節奏,部分項目進度延遲,導致上半年完工項目減少,業績出現下滑;互聯網移動信息服務因加大了業務開發力度,銷售收入與去年同比增長40.10%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.